Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Share-based Compensation (2022 - 2025)

Prokidney (PROK) has disclosed Share-based Compensation for 4 consecutive years, with $5.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 173.53% to $5.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.9 million through Dec 2025, up 3.2% year-over-year, with the annual reading at $25.3 million for FY2025, 3.37% up from the prior year.
  • Share-based Compensation for Q4 2025 was $5.7 million at Prokidney, down from $5.9 million in the prior quarter.
  • The five-year high for Share-based Compensation was $52.7 million in Q1 2022, with the low at -$6.4 million in Q4 2023.
  • Average Share-based Compensation over 4 years is $9.2 million, with a median of $6.7 million recorded in 2024.
  • The sharpest move saw Share-based Compensation crashed 171.24% in 2023, then soared 173.53% in 2025.
  • Over 4 years, Share-based Compensation stood at $8.9 million in 2022, then plummeted by 171.24% to -$6.4 million in 2023, then surged by 132.74% to $2.1 million in 2024, then soared by 173.53% to $5.7 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $5.7 million, $5.9 million, and $5.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.